Login to Your Account

InterMune Bulks Up Balance Sheet for Esbriet EU Launch

By Jennifer Boggs

Thursday, September 15, 2011
Set to make idiopathic pulmonary fibrosis drug Esbriet (pirfenidone) available to patients in Germany Thursday, about six months after receiving European approval, InterMune Inc. is bolstering its cash position via two public offerings totaling $231 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription